{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002222","form_type":"8-K","ticker":"ITGR","cik":"0001114483","company_name":"Integer Holdings Corp","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.338727+00:00","generated_at":"2026-06-03T07:27:31.328170+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Integer Q1 sales up 10% to $415M, adjusted EPS $1.14; reiterates FY2024 outlook","bullets":["Sales of $415M (+10% YoY), organic growth 6%; GAAP net income $21M (+57%), diluted EPS $0.59.","Non-GAAP adjusted net income $39M (+33%), adjusted EPS $1.14 vs $0.87; adjusted EBITDA $81M (+22%).","Total debt $1.141B (up $181M) to finance Pulse acquisition; leverage ratio 3.4x adjusted EBITDA.","Cardio & Vascular sales +16%; Cardiac Rhythm & Neuromodulation +8%; Electrochem declined.","FY2024 outlook reaffirmed: sales $1.735-1.770B (9-11% growth), adjusted EPS $5.01-$5.43."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002222","json":"https://secwatch.observer/filing/0001171843-24-002222.json","markdown":"https://secwatch.observer/filing/0001171843-24-002222.md","text":"https://secwatch.observer/filing/0001171843-24-002222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114483/000117184324002222/0001171843-24-002222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114483/000117184324002222/f8k_042524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:27:31.328170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8bd9203cc9e129722105df999d771c7525bce684","claim":"Integer Holdings Corp reported the first quarter ended March 29, 2024 results: revenue $415 million, net income $21 million, EPS $0.59 per share. Guidance reaffirmed.","evidence_excerpt":"today announced results for the three months ended March 29, 2024. First Quarter 2024 Highlights (compared to First Quarter 2023, except as noted) Sales increased 10% to $415 million, with organic growth of 6%. GAAP net income increased $7 million to $21 million, an increase of 57%. Non-GAAP adjusted net income increased $10 million to $39 million, an","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1114483/000117184324002222/0001171843-24-002222-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 29, 2024"},{"label":"Revenue","value":"$415 million"},{"label":"Net income","value":"$21 million"},{"label":"EPS","value":"$0.59 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}